These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 20829696)
21. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Ensinck MM; Carlon MS Cells; 2022 Jun; 11(12):. PubMed ID: 35740997 [TBL] [Abstract][Full Text] [Related]
23. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
24. An overview on chemical structures as ΔF508-CFTR correctors. Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599 [TBL] [Abstract][Full Text] [Related]
25. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. Birault V; Solari R; Hanrahan J; Thomas DY Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435 [TBL] [Abstract][Full Text] [Related]
26. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
27. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Merk D; Schubert-Zsilavecz M Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506 [TBL] [Abstract][Full Text] [Related]
28. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. Farinha CM; Matos P; Amaral MD FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Arora K; Naren AP Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081 [TBL] [Abstract][Full Text] [Related]
30. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391 [TBL] [Abstract][Full Text] [Related]
31. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Loo TW; Bartlett MC; Clarke DM Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259 [TBL] [Abstract][Full Text] [Related]
32. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489 [TBL] [Abstract][Full Text] [Related]
33. New horizons in the treatment of cystic fibrosis. Cuthbert AW Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631 [TBL] [Abstract][Full Text] [Related]
34. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944 [TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Rogan MP; Stoltz DA; Hornick DB Chest; 2011 Jun; 139(6):1480-1490. PubMed ID: 21652558 [TBL] [Abstract][Full Text] [Related]
36. Targeting the Root Cause of Cystic Fibrosis. Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272 [TBL] [Abstract][Full Text] [Related]
37. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
38. Strategies for the etiological therapy of cystic fibrosis. Maiuri L; Raia V; Kroemer G Cell Death Differ; 2017 Nov; 24(11):1825-1844. PubMed ID: 28937684 [TBL] [Abstract][Full Text] [Related]
39. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Amaral MD; Farinha CM Curr Pharm Des; 2013; 19(19):3497-508. PubMed ID: 23331027 [TBL] [Abstract][Full Text] [Related]
40. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]